MURRAY HILL, N.J.--(BUSINESS WIRE)--Dec. 12, 2007--C. R. Bard,
Inc. (NYSE: BCR) today announced that a U.S. District Court jury in
Arizona found that certain of W. L. Gore & Associates Inc.'s ePTFE
vascular grafts and stent-grafts infringe Bard patent number
6,436,135. The jury upheld the validity of the patent and awarded $185
million in past damages. The jury also found that Gore willfully
infringed the patent.
In a second phase of the trial, the court is currently assessing
Gore's assertion that the patent is unenforceable due to inequitable
Bard expects that Gore will file post-trial motions with the court
with respect to the jury's decision. After a judgment is entered, the
case may be appealed to the Court of Appeals for the Federal Circuit.
C. R. Bard, Inc., (www.crbard.com) headquartered in Murray Hill,
N.J., is a leading multinational developer, manufacturer and marketer
of innovative, life-enhancing medical technologies in the fields of
vascular, urology, oncology and surgical specialty products.
This press release may contain forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995,
which are based on management's current expectations, the accuracy of
which is necessarily subject to risks and uncertainties. These
statements are not historical in nature and use words such as
"anticipate", "estimate", "expect", "project", "intend", "forecast",
"plan", "believe", and other words of similar meaning in connection
with any discussion of future operating or financial performance. Many
factors may cause actual results to differ materially from anticipated
results including product developments, sales efforts, income tax
matters, the outcomes of contingencies such as legal proceedings, and
other economic, business, competitive and regulatory factors. The
company undertakes no obligation to update its forward-looking
statements. Please refer to the Cautionary Statement Regarding
Forward-Looking Information in our September 30, 2007 Form 10-Q/A for
more detailed information about these and other factors that may cause
actual results to differ materially from those expressed or implied.
CONTACT: C. R. Bard, Inc.
Eric J. Shick, 908-277-8413
Vice President, Investor Relations
Holly P. Glass, 703-754-2848
Vice President, Government and Public Relations
SOURCE: C. R. Bard, Inc.